Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: March 03, 2026 - **Key Speakers**: Sam Raha (President and CEO), Ben Wheeler (CFO) Core Industry Insights - **Industry Focus**: Cancer care continuum, hereditary cancer testing, mental health pharmacogenomics, prenatal health - **Market Size**: Hereditary cancer testing market is valued at approximately $7 billion, with growth opportunities in high single digits Key Points and Arguments Strategic Priorities and Performance - **CEO Transition**: Sam Raha has been in the CEO role since April 30, 2025, focusing on redefining Myriad's strategy and priorities [4] - **Positive Developments**: Increased energy and enthusiasm within the company, successful recruitment of new talent, and a disciplined approach to growth in cancer care and other high-growth applications [5][6] - **Challenges**: Encountered delays in the rollout of a new order management system for the prenatal business, impacting execution [7] Financial Performance - **2025 Challenges**: Faced headwinds from UnitedHealthcare's policy changes affecting mental health pharmacogenomics, resulting in a revenue loss of over $40 million [10] - **2026 Guidance**: Projected revenue growth of 6% for 2026, with total revenue expected to be between $860 million and $880 million [9][15] - **Volume Growth**: GeneSight volume grew by 9% in Q4, indicating recovery and stabilization after a challenging year [11] Product Development and Launches - **New Product Focus**: Plans to launch more products in the next 18 months than in the previous five years, particularly in the cancer care continuum [7][8] - **Hereditary Cancer Testing**: Anticipated growth in hereditary cancer testing volume in 2026, with a focus on the MyRisk panel, which saw a 13% growth in Q4 [30] - **MRD Technology**: Introduction of the Precise MRD assay, an ultrasensitive test aimed at low-shedding cancers, with a focus on community oncology [34][35] Competitive Differentiation - **FirstGene Launch**: A combined carrier and prenatal screening test set to launch in the second half of 2026, designed for convenience and efficiency [54][55] - **AI-Enhanced Prolaris Test**: Scheduled for launch in Q2 2026, combining molecular and AI capabilities to improve decision-making in prostate cancer treatment [44][46] Market Dynamics and Regulatory Environment - **Biomarker Legislation**: Over 20 states have enacted biomarker laws, providing opportunities for Myriad's tests, particularly in cancer MRD and GeneSight [62][63] - **Payer Landscape**: Successfully added 12 payers for GeneSight coverage in 2025, with expectations for continued growth in 2026 [52] Financial Outlook and Profitability - **Adjusted EBITDA Guidance**: Expected adjusted EBITDA for 2026 is between $37 million and $49 million, with a focus on achieving free cash flow positivity [67][68] - **Capital Expenditure**: Anticipated CapEx of $20 million to $30 million annually for software and hard CapEx [68] M&A and Strategic Partnerships - **Focus on Partnerships**: Emphasis on strategic partnerships rather than M&A to enhance growth opportunities in the cancer care continuum [69] Conclusion and Investor Sentiment - **Growth Potential**: Myriad Genetics is positioned for high single-digit to low double-digit growth while maintaining profitability, with a strong focus on execution and accountability [70][72] - **Market Positioning**: The company aims to transition from a participant to a market-defining entity in the cancer care space [71]

Core Insights - Myriad Genetics reported fourth quarter revenue of approximately $210 million, exceeding the high end of its pre-announced range, with overall test volumes increasing by 2% year-over-year and underlying revenue growth of 4% after adjusting for an $8.1 million headwind from UnitedHealthcare's GeneSight coverage policy [3][7][2] Financial Performance - The company achieved consolidated revenue of $209.8 million, consistent with the previous year, and delivered 382,000 test results in the quarter [3][7] - Adjusted EBITDA for the quarter was reported at $14.3 million, with adjusted operating cash flow of $17.9 million and adjusted EPS of $0.04 [13] - Fourth quarter gross margin was 70%, down approximately 190 basis points year-over-year, attributed to the GeneSight revenue headwind [12] Segment Performance - In oncology, revenue reached $84.7 million, reflecting a 2% increase year-over-year, with MyRisk showing 14% volume growth in the affected market and 11% in the unaffected market [8][9] - Prolaris revenue growth accelerated to 16% year-over-year, driven by 12% volume growth, with investments in commercial channels to regain market share [9] - Women's health revenue was reported at $88.5 million, up 2% year-over-year, with hereditary cancer testing showing 3% revenue growth and 11% volume growth [9] Product Launches and Future Guidance - The company reaffirmed its full-year 2026 guidance of $860–880 million in revenue, with an adjusted gross margin of 68–69% and adjusted EBITDA of $37–49 million [5][14] - Myriad plans to launch an AI-enhanced Prolaris test in Q2 2026 and a full commercial launch of FirstGene prenatal screening in H2 2026 [6][15] - Management is reorganizing reporting into three strategic areas: cancer care continuum, prenatal health, and mental health, with a dedicated prenatal sales team [5][16] Operational Updates - Prenatal testing volumes declined year-over-year due to disruptions from a new test ordering system, but management is in an "active rebuild phase" to reactivate accounts and expand access [10] - GeneSight revenue for the fourth quarter was $36.6 million, supported by 9% year-over-year volume growth, with an expanded provider base of over 38,000 clinicians [11]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting disciplined cost management and strategic investments [8][28] - The adjusted gross margin for the fourth quarter was 70%, down approximately 190 basis points year-over-year due to the revenue headwind from GeneSight [9][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, reflecting a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] Market Data and Key Metrics Changes - GeneSight volume grew 9% year-over-year, with a record number of ordering clinicians reaching over 38,000 [22] - The company faced challenges in prenatal testing, with a decline in volume due to order management disruptions, but expects recovery in 2026 [21][22] - The mental health segment showed resilience, with GeneSight revenues impacted by UnitedHealthcare's coverage policy change but still achieving positive coverage policies across 12 payers [23] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in the cancer care continuum [15][60] - The company aims to strengthen its position across cancer care testing while leveraging operational strengths for sample processing and reporting [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and expects to regain share in the prenatal market [20][21] - Management emphasized the importance of execution excellence and rigorous testing before launching new products to avoid past issues [82] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [31] - The company maintains a solid balance sheet with access to $225 million in capital and intends to file a universal shelf registration [28] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted several growth drivers for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team and new product launches [44][76] Question: Prolaris momentum - Management noted that various initiatives, including engagement with KOLs and sales team expansion, contributed to Prolaris' growth, while also acknowledging potential favorable comparisons in Q4 [71][73]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [4][24] - For the full year 2025, total revenue was $824.5 million, with over 1.5 million test reports delivered [6] - Adjusted gross margin for the fourth quarter was 70%, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04 [7][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, reflecting a 2% growth year-over-year, with MyRisk test volume growing 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight generated revenues of $36.6 million with a 9% year-over-year volume growth [21] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers, with GeneSight achieving a record number of ordering clinicians exceeding 38,000 [6][21] - The prenatal testing segment experienced a decline in volume due to previous order management disruptions, but recovery is expected in 2026 [20][22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and AI-enhanced Prolaris test [4][9] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in cancer care [15][30] - The company aims to strengthen its position across cancer care testing while expanding its commercial capabilities and customer reach [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the ongoing demand for its products and the positive momentum in hereditary cancer testing and GeneSight volumes [23][24] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [30] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [12][17] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38][39] Question: MRD launch strategy - The company plans to be selective during the alpha phase of the MRD launch, focusing on user experience and operational efficiency before scaling up [41][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team [44][78] Question: Prolaris momentum and dynamics - Management noted that various initiatives contributed to Prolaris growth, including engagement with key opinion leaders and expansion of the sales team [72][75] Question: GeneSight ASP trends - Management indicated that the trend in average selling price (ASP) for GeneSight is expected to improve as the company engages with payers and secures positive coverage policies [88]

Fourth Quarter and Full Year 2025 Earnings Call F E B R U A R Y 2 3 , 2 0 2 6 ©2026 Myriad Genetics, Inc. Forward-looking statements and Non-GAAP financial measures Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management's current expectations and the actual events or results may differ materially and adv ...

Core Insights - Myriad Genetics reported financial results for Q4 2025, showing stable revenue but a slight decline in full-year revenue for 2025, with expectations for growth in 2026 driven by new test launches [2][5][15] Financial Performance - Q4 2025 revenue was $209.8 million, consistent with Q4 2024, but grew 4% year-over-year when excluding an $8.1 million headwind [5][21] - Full-year 2025 revenue was $824.5 million, a decrease of 2% year-over-year, but grew 2% when excluding headwinds [5][21] - Q4 2025 gross margin was 70.0%, in line with Q3 2025 [5] - The company reported a GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share [5][24] Operational Highlights - Total test volumes in Q4 2025 were 382,000, a 2% increase year-over-year [6] - Hereditary cancer testing volume grew by 9% year-over-year, while Prolaris prostate cancer test volume increased by 12% [5][11] - The Women's Health business generated $88.5 million in revenue in Q4 2025, while the Oncology business generated $84.7 million [9][12] Future Outlook - The company plans to launch three significant new tests in 2026, including Precise MRD for breast cancer, AI-enabled Prolaris, and FirstGene prenatal screen [3][15] - Full-year 2026 revenue guidance is set between $860 million and $880 million, with Q1 2026 revenue expected to be between $200 million and $203 million [15][14] Cash Flow and Liquidity - Q4 2025 cash flow from operations was $10.6 million, with adjusted operating cash flow of $17.9 million [8] - As of the end of Q4 2025, the company had cash and cash equivalents of $149.6 million [8][26]

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Industry**: Precision medicine and diagnostic testing - **Key Leadership**: Sam Raha (President and CEO), Ben Wheeler (CFO) [1][2] Core Points and Arguments Company Mission and Market Position - Myriad Genetics has a noble purpose to advance health and well-being, being a leader in precision medicine for over 30 years [2] - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025 [3] Strategic Focus - The company is at an inflection point, focusing on the cancer care continuum and expanding its product portfolio beyond hereditary cancer [3][5] - Emphasis on execution excellence, utilizing AI across operations, product development, and customer experience [4][5] Market Opportunities - The total market opportunity for Myriad is estimated at $40 billion, with many served markets growing in double digits and having less than 50% market penetration [6] - Hereditary cancer testing represents a $7 billion market, with Myriad's myRisk test being the gold standard [9][10] Product Development and Launches - Upcoming launches include disease-specific panels for hereditary cancer and an AI-enabled Prolaris test for prostate cancer [10][13] - The company plans to expand its offerings in minimal residual disease (MRD) testing, starting with breast cancer, which has a $7 billion total addressable market (TAM) [19] Financial Performance and Projections - Projected revenue for 2025 is between $822 million and $824 million, with a 6% growth expected for 2026, targeting $860 million to $880 million [28][31] - The company aims to maintain industry-leading gross margins of 68%-69% while reducing costs [31][32] Growth Catalysts - Key growth drivers include the performance of hereditary cancer products, timely launches of new products, and consistent execution of financial and operational goals [38][40] - The company is investing over $35 million to strengthen commercial capabilities related to the cancer care continuum [30][52] Additional Important Content Partnerships and Collaborations - Myriad is exploring strategic partnerships to enhance its market position and product offerings, particularly in the cancer care continuum [45] - Collaborations with Sophia Genetics and MSK are aimed at biomarker selection and companion diagnostic development [12][45] Challenges and Market Dynamics - The prenatal health segment faced a 4% decline in 2025 due to implementation challenges, but recovery efforts are underway [29][30] - Mental health remains a growing area, with the GeneSight test being a market leader, having provided results for over three million patients [26][27] Long-term Vision - Myriad Genetics aims for high-single-digit to low-double-digit revenue growth over the next five years, supported by a robust pipeline of new products and strategic initiatives [33][36] This summary encapsulates the key insights from the Myriad Genetics FY Conference, highlighting the company's strategic direction, market opportunities, financial outlook, and growth initiatives.

Core Insights - Tempus AI has initiated partnerships with leading academic medical centers, including NYU Langone Health and Northwestern Medicine, to enhance access to advanced genomic testing and data-driven cancer care [2][4]. Group 1: Partnerships and Collaborations - The collaboration with NYU Langone Health focuses on improving genetic diagnostics and accelerating the development of new tests and data-driven tools [2][3]. - Tempus is expanding its role in next-generation sequencing (NGS) testing to include test validation, biomarker discovery, disease modeling, and AI-driven prediction tools [3]. - The partnership with Northwestern Medicine aims to provide nearly all cancer patients, including those diagnosed at early stages, access to genetic testing [4][5]. Group 2: Testing and Treatment - Tempus will support Northwestern Medicine by offering a variety of genomic tests, including tissue testing, DNA and RNA profiling, liquid biopsy, and minimal residual disease (MRD) testing [5]. - These genomic tests are designed to help doctors understand each patient's cancer better and select more personalized and effective treatments [5]. Group 3: Market Performance - Tempus' stock has increased by 114.3% over the past year, significantly outperforming the industry growth of 4.3% and the S&P 500's 22% increase during the same period [8]. Group 4: Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 7.84X, which is higher than the industry average of 5.77X [10]. Group 5: Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has narrowed by 1 cent to 64 cents over the past 30 days [11].

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: December 02, 2025 Key Industry Insights - **Hereditary Cancer Market**: The unaffected population represents a $5 billion market opportunity, with significant growth potential as it remains less than a third penetrated [2][21] - **Mental Health Market**: Myriad Genetics is a market leader in mental health testing, with plans to maintain growth despite challenges from competitors [16][19] Core Company Strategies - **Focus on Cancer Care**: The updated strategy emphasizes a concentrated effort on the cancer care continuum, while managing growth in prenatal and mental health segments [3][8] - **Product Development**: Introduction of new products such as FirstGene and Early Access for prenatal screening, and an updated MyRisk product with 63 genes [7][10] - **Execution Excellence**: Acknowledgment of the need for improved execution in product development and market launch processes [3][4] Financial Performance - **Growth Metrics**: Mid-single-digit growth observed in GeneSight tests, with a return to growth in hereditary cancer testing after previous challenges [6][21] - **Revenue Projections**: GeneSight expected to generate over $150 million in revenue, with potential for mid-single to low double-digit growth rates [16][17] Competitive Landscape - **Market Positioning**: Myriad Genetics aims to differentiate itself from competitors like Natera and BillionToOne by leveraging its comprehensive product offerings and customer support [8][9] - **Guideline Engagement**: Active collaboration with Key Opinion Leaders (KOLs) to clarify NCCN guidelines and enhance the adoption of Myriad's Prolaris test for prostate cancer [12][13] Product Pipeline and R&D Focus - **MRD Testing**: Introduction of the Precise MRD assay, expected to launch in the first half of 2026, with a focus on low-shedding cancers [25][26] - **Partnerships**: Collaborations with Pathomic to accelerate R&D and market entry for new tests [29][33] - **Clinical Studies**: Over 20 studies in MRD across various cancer indications, with results expected to enhance clinical utility and guideline positioning [28][30] Challenges and Opportunities - **Reimbursement Issues**: Navigating reimbursement challenges, particularly with UnitedHealth's policy, while expanding payer coverage [16][20] - **Market Activation**: Efforts to activate the unaffected hereditary cancer market through improved workflows and sales strategies [22][23] Conclusion - Myriad Genetics is strategically positioning itself for growth in the hereditary cancer and mental health markets, with a strong focus on execution excellence and product innovation. The company is optimistic about its future prospects, particularly with the anticipated launch of new products and ongoing collaborations.